Moreover, targeting SSTR2 with specific modulators may disrupt the VEGFR, PDGFR, and RAF/MEK/ERK pathways, offering a synergistic approach with sorafenib to inhibit tumor growth and angiogenesis more effectively. This evidence concerns the gene MAP2K7 and neoplasm.